IgA Nephropathy (IgAN) - Epidemiology Forecast - 2032

Key Highlights:

• IgA Nephropathy (IgAN) is an autoimmune disease that attacks the kidneys and affects blood filtration in the small blood vessels of the kidneys. It occurs when an abnormal protein damages the kidneys' filtering unit (glomerulus).
• The diagnosis of IgAN relies on revealing IgA as the dominant or co-dominant immunoglobulin in the glomerular mesangium by kidney biopsy. Although renal biopsy remains the gold standard for IgAN diagnosis, recent efforts have sought new biomarkers to predict IgAN without needing a biopsy. However, unclear pathogenesis complicates noninvasive diagnosis.
• According to the estimates, in 2022, the highest number of prevalent cases of IgA Nephropathy (IgAN) were observed in the United States among the 7MM.
• Most IgA Nephropathy patients are diagnosed accidentally, with approximately 23,000 diagnosed cases in Germany in 2022.
• In 2022, Spain accounted for the lowest diagnosed prevalent population of IgA Nephropathy (IgAN) out of all the 7MM countries.

The “IgA Nephropathy (IgAN) - Epidemiology Forecast - 2032” report delivers an in-depth understanding of the IgA Nephropathy (IgAN), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, Japan, and China.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan
• China

Study Period: 2019-2032

IgA Nephropathy (IgAN) Understanding and Diagnostic Algorithm

IgA Nephropathy (IgAN) Overview

IgA Nephropathy (IgAN) is an autoimmune condition affecting the kidneys' small blood vessels and filtration. It happens when an abnormal protein harms the filtration system in the kidneys.

The most prevalent glomerular disease in the world is IgAN, but the prevalence differs significantly by region. IgAN is more common in Asian populations than in Western populations, according to epidemiological study studies.

IgA Nephropathy (IgAN) Diagnosis

The diagnosis of IgAN relies on revealing IgA as the dominant or co-dominant immunoglobulin in the glomerular mesangium by kidney biopsy. Although renal biopsy is still the gold standard for diagnosing IgAN, novel biomarkers to predict IgAN without a biopsy have recently been sought after. But uncertain pathogenesis makes noninvasive diagnosis more difficult.

A nonprofit organization called Kidney Disease: Improving Global Outcomes (KDIGO) creates and puts evidence-based clinical practice recommendations for kidney diseases into practice. The Clinical Practice Guideline for Glomerulonephritis was released by KDIGO in 2012, and KDIGO also published a draught revision of these recommendations in 2020.

IgA Nephropathy (IgAN) Epidemiology

The epidemiology forecast model of IgA Nephropathy (IgAN) for the 7MM and China is based on the prevalence of IgAN in the overall population to calculate the prevalent cases of IgAN. From this, the diagnosis rate was applied to calculate the diagnosed prevalent cases of IgAN.

The IgA Nephropathy epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by prevalent cases of IgA Nephropathy, diagnosed prevalent cases of IgA, gender-specific cases of IgA Nephropathy, and age-specific cases of IgA Nephropathy in the 7MM and China covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, Japan, and China from 2019 to 2032. The total prevalent cases of IgA Nephropathy in the 7MM and China comprised approximately 1,899,000 cases in 2022 and are projected to increase during the forecasted period

• The total number of prevalent cases of IgA Nephropathy in the United States was around 194,000 cases in 2022.
• The United States contributed to the largest prevalent population of IgA Nephropathy in the 7MM, acquiring ~40% of the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 34% and 26% of the total prevalent population share of the 7MM, respectively, in 2022.
• Among the EU4 countries, Germany accounted for the largest IgA Nephropathy prevalent cases, followed by France, whereas Spain accounted for the lowest prevalent cases in 2022.
• According to the estimates, there were around 1,414,000 prevalent cases of IgA Nephropathy in China in 2022. The prevalence is projected to increase during the forecasted period.
• Japan accounted for about 88,000 diagnosed prevalent cases of IgA Nephropathy in 2022.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of IgA Nephropathy (IgAN), explaining its causes, signs and symptoms, pathogenesis, and diagnosis.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of diagnosis rate, and insights on disease progression have been provided.
• Patient stratification based on gender-specific cases and age-specific cases is an inclusion.
• A detailed review of current challenges in establishing the diagnosis.

IgA Nephropathy (IgAN) Report Insights

• IgA Nephropathy (IgAN) Patient Population
• Gender-wise and Age-wise Patient Population
• Country-wise Epidemiology Distribution

IgA Nephropathy (IgAN) Report Key Strengths

• 10 years Forecast
• The 7MM+China Coverage
• IgA Nephropathy (IgAN) Epidemiology Segmentation

IgA Nephropathy (IgAN) Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions Answered

Epidemiology Insights

• What are the disease risks and burdens of IgA Nephropathy (IgAN)? What will be the growth opportunities across the 7MM and China with respect to the patient population of IgA Nephropathy (IgAN)?
• What is the historical and forecasted IgA Nephropathy (IgAN) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, Japan, and China?
• Which gender is the largest contributor to the IgA Nephropathy (IgAN) patient pool?
• Which age group contributes more to IgA Nephropathy (IgAN) in the 7MM and China?
• What factors affect the increase in the IgA Nephropathy (IgAN) diagnosis rate?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in IgA Nephropathy (IgAN) diagnosed prevalent cases in varying geographies over the coming years.
• A detailed overview of age-specific and gender-specific IgA Nephropathy (IgAN) cases is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis, recurrent cases, and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.